Latest Depression News

Actinogen Medical’s pivotal XanaMIA Alzheimer’s trial stays on track for November topline results, buoyed by strong open-label extension enrolment and aligned EMA-FDA regulatory advice. A new antidepressant study publication and fresh patents add momentum, supported by a $16.7 million cash runway to mid-2027.

Emyria has expanded its Empax clinic network across four states, reporting a 210% revenue increase in FY26 and early clinical success in treatment-resistant depression.

BLS Pharmaceuticals capped FY26 with record revenue and EBITDA, boosted by international expansion and major contracts, setting the stage for further growth in FY27.

Atturra reports FY26 underlying EBITDA in line with guidance despite softer revenue and announces a significant non-cash goodwill impairment tied to government contracts. The company plans substantial FY27 investment in AI, ERP, and education technology to drive organic growth.

Entropy Neurodynamics has reported breakthrough Phase 2 clinical results for its intravenous psilocin therapy in treatment-resistant Binge Eating Disorder, alongside strong Phase 2a data in Irritable Bowel Syndrome and a new US patent filing.

Actinogen Medical’s phase 2 trial of Xanamem in major depressive disorder with cognitive impairment reveals meaningful antidepressant effects, published in the British Journal of Psychiatry. The drug was safe and well-tolerated but did not improve cognition.

Nexalis Therapeutics has issued share rights to directors in lieu of fees, with vesting contingent on successful Phase 2 clinical trial completion, aiming to conserve cash for ongoing drug development.

Rapid Critical Metals has delivered standout metallurgical flotation results from its New South Wales silver projects, with silver recoveries nearing 99% and high-grade concentrates reinforcing project potential.

Nexalis Therapeutics has ended funding negotiations with Point8 Capital after failing to secure a formal agreement, while successfully completing its IRX-616a Phase 1 trial with no serious adverse events. The company is reassessing clinical priorities amid funding uncertainty.

Emyria’s new treatment-resistant depression program shows statistically significant symptom improvements in a small initial cohort, expanding its mental health therapy offerings beyond PTSD.

Actinogen Medical’s pivotal XanaMIA Alzheimer’s trial has passed a third independent safety review, endorsing continuation without changes. Final topline efficacy data is expected in November 2026.

Emyria Limited is progressing its national network of psychedelic-assisted therapy clinics, reporting durable patient outcomes, expanding funding sources, and benefiting from regulatory changes that broaden therapist eligibility.